Compare IMVT & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMVT | ARE |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.9B |
| IPO Year | 2019 | 1997 |
| Metric | IMVT | ARE |
|---|---|---|
| Price | $40.20 | $51.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 11 |
| Target Price | $33.00 | ★ $56.22 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 05-28-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 11.40% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $3,026,556,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.15 |
| P/E Ratio | ★ N/A | $30.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.58 | $39.41 |
| 52 Week High | $45.42 | $88.24 |
| Indicator | IMVT | ARE |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 51.06 |
| Support Level | $37.16 | $48.24 |
| Resistance Level | $41.22 | $55.25 |
| Average True Range (ATR) | 1.39 | 1.61 |
| MACD | -0.36 | 0.23 |
| Stochastic Oscillator | 0.74 | 59.91 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.